The ECOG specimen banks are a critical part of a rapidly expanding program of translational science in ECOG. They are also a valuable resource available to clinical and basic scientists both at ECOG member institutions and at non-ECOG sites. ECOG is enthusiastic about the establishment of the Group Banking Committee (GBC) and is committed to working with the committee to establish uniform policies and ensuring the availability of valuable specimens and data. A stable and adequate funding base will be the first essential step in securing the full potential for our correlative research, within ECOG and throughout the entire system. Specifically, ECOG proposes as its specific aims: 1) To assure the infrastructure needed to enable the Group to maintain its future tissue banking activities at their current breadth of scope and high degree of quality. 2) To provide high quality banks of uniformly collected specimens with validated clinical and outcome data. 3) To act as a collaborator and coordinator in the undertakings of the GBC's efforts. 4) To make available its banks to other investigators {ECOG investigations and external investigators) in order to promote research and clinical advancements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA114737-05
Application #
7618014
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Lubensky, Irina
Project Start
2005-08-19
Project End
2012-03-31
Budget Start
2009-04-01
Budget End
2012-03-31
Support Year
5
Fiscal Year
2009
Total Cost
$896,176
Indirect Cost
Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215
Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875
Gu, Zhaohui; Churchman, Michelle; Roberts, Kathryn et al. (2016) Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331
Iacobucci, Ilaria; Li, Yongjin; Roberts, Kathryn G et al. (2016) Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29:186-200
Churchman, Michelle L; Low, Jonathan; Qu, Chunxu et al. (2015) Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell 28:343-56
DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J et al. (2015) A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 68:365-71
Perez-Andreu, Virginia; Roberts, Kathryn G; Xu, Heng et al. (2015) A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125:680-6
Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41
Park, Sun-Mi; Gönen, Mithat; Vu, Ly et al. (2015) Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest 125:1286-98
Villaruz, Liza C; Huang, Grace; Romkes, Marjorie et al. (2015) MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics 7:58
Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485

Showing the most recent 10 out of 165 publications